RenovoRx stockholders elect directors, approve equity plan amendment, ratify auditor at 2026 annual meeting

RenovoRx, Inc.

All six director nominees elected with 12.9M+ votes for each; broker non-votes of 9.6M.
Amendment to 2021 Omnibus Equity Incentive Plan approved: 9.7M for, 3.6M against; adds 2,000,000 shares (4.4% of outstanding).
Ratification of Frank, Rimerman + Co. LLP as auditor for FY 2026: 21.9M for, 477k against.
Approximately 22.8M shares (50.6% of 45.1M outstanding) present or represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.